Last reviewed · How we verify
NCT02215837
Randomized,Controlled,Multicenter Study of Autologous Tumor Lysate-pulsed Dendritic and Cytokine-induced Killer Cells(Ag-D-CIK) Combined With Chemotherapy for Gastric Cancer.
Phase 2 trial testing Chemotherapy in Gastric Cancer in 40 participants. Status unknown.
1 May 2018
Quick facts
| Lead sponsor | Shenzhen Hornetcorn Bio-technology Company, LTD |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 1 August 2014 |
| Primary completion | 1 May 2018 |
| Estimated completion | 1 May 2018 |
| Sites | 2 locations across China |
Drugs / interventions tested
- Chemotherapy (chemotherapy) — full drug profile →
- Ag-D-CIK — full drug profile →
Conditions studied
- Gastric Cancer — all drugs for Gastric Cancer →
- Neoplasms — all drugs for Neoplasms →
- Gastrointestinal Neoplasms — all drugs for Gastrointestinal Neoplasms →
- Digestive System Neoplasms — all drugs for Digestive System Neoplasms →
Sponsor
Shenzhen Hornetcorn Bio-technology Company, LTD — full company profile →
Who can join
Adults 18 to 80, any sex, with Gastric Cancer or Neoplasms. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Progress-free survival
Time frame: 3 years
Sponsor's own description
The purpose of this study is to evaluate the safety and efficacy of chemotherapy combined with autologous tumor Lysate-pulsed dendritic with cytokine-induced killer cell (Ag-D-CIK) for gastric cancer.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy.
Pol J, Vacchelli E, Aranda F, Castoldi F, et al · · 2015 · cited 238× · PMID 26137404 · DOI 10.1080/2162402x.2015.1008866 -
Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy.
Gao X, Mi Y, Guo N, Xu H, et al · · 2017 · cited 109× · PMID 28729866 · DOI 10.3389/fimmu.2017.00774 -
Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer.
Versteven M, Van den Bergh JMJ, Marcq E, Smits ELJ, et al · · 2018 · cited 75× · PMID 29599770 · DOI 10.3389/fimmu.2018.00394 -
Cytokine-induced killer (CIK) cells: from basic research to clinical translation.
Guo Y, Han W. · · 2015 · cited 50× · PMID 25962508 · DOI 10.1186/s40880-015-0002-1 -
Trial Watch: Adoptive cell transfer for oncological indications.
Aranda F, Buqué A, Bloy N, Castoldi F, et al · · 2015 · cited 28× · PMID 26451319 · DOI 10.1080/2162402x.2015.1046673 -
Tumor-derived systems as novel biomedical tools-turning the enemy into an ally.
Desai N, Katare P, Makwana V, Salave S, et al · · 2023 · cited 20× · PMID 37946275 · DOI 10.1186/s40824-023-00445-z -
Advances in Human Dendritic Cell-Based Immunotherapy Against Gastrointestinal Cancer.
Ni L. · · 2022 · cited 16× · PMID 35619702 · DOI 10.3389/fimmu.2022.887189 -
Cytokine-Induced Killer Cells: A Unique Platform for Adoptive Cell Immunotherapy after Allogeneic Hematopoietic Stem Cell Transplantation.
Rettinger E. · · 2025 · cited 3× · PMID 39944412 · DOI 10.1159/000540964
Verify or expand the search:
- PubMed search for NCT02215837
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Chemotherapy
Trials testing the same drug.
- NCT07391774 — Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribocic · Phase 3 · not yet recruiting
- NCT07476287 — Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult · Phase 2 · recruiting
- NCT07392892 — A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer · Phase 2, PHASE3 · recruiting
- NCT07288034 — Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatmen · Phase 2 · recruiting
- NCT07078604 — A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negati · Phase 2 · recruiting
Other recruiting trials for Gastric Cancer
Currently open trials in the same condition.
- NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
- NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
- NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02215837 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shenzhen Hornetcorn Bio-technology Company, LTD
- Last refreshed: 23 May 2016
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02215837.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing